03.13.18
Dr. June Almenoff has been appointed chief operating officer and chief medical officer, Innovate Biopharmaceuticals, Inc. Dr. Almenoff brings more than 20 years of pharmaceutical executive experience from GlaxoSmithKline and from Furiex Pharmaceuticals.
Dr. Almenoff previously served as president and chief medical officer at Furiex Pharmaceuticals, where during her tenure the company’s valuation increased ~10-fold, culminating in its acquisition by Actavis plc (now Allergan) for more than $1.2B in 2014. Prior to joining Furiex, Dr. Almenoff held various positions of increasing responsibility at GlaxoSmithKline over 12 years, including vice president in the Clinical Safety organization. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which has been widely adopted by industry and regulators.
“Dr. Almenoff’s tremendous business leadership experience makes her an outstanding fit for Innovate,” said Sandeep Laumas, M.D., executive chair of Innovate. “June’s successes at Furiex and extensive experience in drug development, coupled with her scientific and business leadership, make us confident that she will provide meaningful contributions to the Company, beginning with our celiac disease program. As our pipeline continues to expand with indications such as NASH and inflammatory bowel disease, we are thrilled to have someone of June’s caliber lead their development and commercial strategy.”
Dr. Almenoff previously served as president and chief medical officer at Furiex Pharmaceuticals, where during her tenure the company’s valuation increased ~10-fold, culminating in its acquisition by Actavis plc (now Allergan) for more than $1.2B in 2014. Prior to joining Furiex, Dr. Almenoff held various positions of increasing responsibility at GlaxoSmithKline over 12 years, including vice president in the Clinical Safety organization. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which has been widely adopted by industry and regulators.
“Dr. Almenoff’s tremendous business leadership experience makes her an outstanding fit for Innovate,” said Sandeep Laumas, M.D., executive chair of Innovate. “June’s successes at Furiex and extensive experience in drug development, coupled with her scientific and business leadership, make us confident that she will provide meaningful contributions to the Company, beginning with our celiac disease program. As our pipeline continues to expand with indications such as NASH and inflammatory bowel disease, we are thrilled to have someone of June’s caliber lead their development and commercial strategy.”